Phylloceuticals has entered into a multi-year partnership with Acumen Analytics to foster discovery, development and commercialization of biologics using AI, blockchain and digital twin technologies.
Acumen Analytics is a WBE advanced analytics and AI consulting company enabling enterprises to transform their data to create strategies and solutions that drive measurable business outcomes. Founded in 2021, Phylloceuticals is a privately held, global technology company dedicated to providing affordable medicine to underserved areas of the world.
As part of the agreement, Acumen Analytics will provide AI and data analytics capabilities for Pharmaceuticals as a Service Technology (PhAAST), the Phylloceuticals service platform designed to provide continuous improvement over all facilities built under Phylloceutical’s guidance. Data security will be a paramount concern, as Phylloceuticals puts facilities in areas of the world where data infrastructure is less developed.
Commenting on the partnership, Kathy Brunner, CEO of Acumen Analytics, said:
“The vision of Phylloceuticals, growing plants to produce proteins for faster, more efficient delivery of drugs to underserved areas of the world, excites us on so many levels. Harnessing and aligning all parts of the organization increases flexibility and agility. We have been helping companies for years, prescriptively collect, analyze and act on a “Single Version of the Truth” – getting the right data in the right place at the right time. This collaboration will enable PhAAST to expedite discovery, development and commercialization of transformative medicines. And we love that it aligns Acumen’s decades of work and expertise with a strong sense of social responsibility.”
Phylloceuticals stated that its founding partners have worked across the pharmaceutical industry for more than three decades. Their separate career paths have brought them together on a variety of award-winning projects. The strength and deep experience of the cross-functional team lies at the heart of the Phylloceuticals model. The company claims to have a complete portfolio of skill sets, including drug development, regulatory strategy and enablement, full scale manufacturing and marketing support for company and product launch.
What is Pharmaceuticals as a Service Technology (PhAAST™)?
PhAAST™, or Pharmaceuticals As A Service Technology, is a unique concept that uses a plant-made technology which offers rapid development of biopharmaceutical products at lower capital expense and operating cost. Drug development and manufacturing can happen fast (PhAAST™), enabling countries and regions to quickly develop reliable supply chains for needed biologics medicines. Rather than relying upon the traditional engineering and construction or CDMO models to deliver manufactured drugs, Phylloceuticals’ model helps nucleate teams to produce independently, with a proven production system and ongoing support from the Phylloceuticals team. Phyllo, which is a Greek work meaning ‘leaf,’ signifies the plant-made technology which fuels the PhAAST™ delivery.
PhAAST™ also includes:
- Harnessing the Digital Thread by leveraging Blockchain and AI to develop Digital Twins
- IIoT, Edge Computing Intelligence, Pervasive sensors, Smart Connected Assets, RPA (robotic process automation) and the Connected Worker
- Real Time Collaborating: Early and Often
- Automating and optimizing workflows to seamlessly orchestrate production
- Simplifying data science and harvesting scalable insights by automating IT/OT convergence
- Enabling lights-out manufacturing
- This platform fosters continuous improvement and can be monitored from anywhere for a reproducible model that can be replicated across regions and markets underserved currently by large pharma.
Bill Brydges, CEO of Phylloceuticals, said:
“Every facility will learn from the one before, with the latest in AI employed, to continuously up our efficiencies at every level, both in aeroponic plant and protein production, as well as facilitating the downstream side of these facilities. Data will be centralized from every facility to truly achieve digital transformation inside these pharmaceutical facilities. We knew quickly that Acumen Analytics understood our vision, and had the experience to both visualize and execute. This data analytics and digital transformation piece is extremely important to our business model.”